Robert Ballou

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, a drug used for early pregnancy termination, were not sufficiently justified. The restrictions, challenged by abortion providers in Kansas, Montana, and Virginia, require special certification for pharmacies and clinicians and risk acknowledgment forms. A similar case in Hawaii had previously reached the same conclusion.

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, including special certification for pharmacies and clinicians and risk acknowledgment forms, are unlawful and must be reviewed. The lawsuit was filed by abortion providers in Kansas, Montana, and Virginia, with a similar case in Hawaii also finding the restrictions arbitrary.

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, including special certification requirements for prescribers and pharmacies, were not sufficiently justified. The decision follows a lawsuit by abortion providers in Kansas, Montana, and Virginia, who argued the restrictions were excessive and inconsistent with legal requirements.

A federal judge ruled that the FDA's 2023 restrictions on mifepristone, an abortion drug, were not sufficiently justified, requiring the agency to reconsider them. The lawsuit, filed by abortion providers in Kansas, Montana, and Virginia, argued the restrictions were excessive and inconsistent with legal requirements. A similar case in Hawaii reached the same conclusion earlier.

A federal judge in Virginia ruled that the FDA's 2023 restrictions on mifepristone, a drug used to terminate early pregnancies, are unlawful due to insufficient justification. The ruling follows similar challenges from abortion providers in Kansas, Montana, and Virginia, who argued the restrictions—requiring special certifications and risk acknowledgment forms—are excessive and medically unnecessary.

A federal judge in Virginia ruled that the FDA's 2023 restrictions on mifepristone, including special certification for pharmacies and risk acknowledgment forms, are unlawful and must be reviewed. The lawsuit, filed by providers in Kansas, Montana, and Virginia, argues the restrictions are excessive and inconsistent with legal requirements.

A federal judge ruled that FDA restrictions on mifepristone, an abortion medication, are arbitrary and capricious, ordering the Trump administration to reconsider the restrictions. The judge affirmed the drug's safety and cited growing barriers to abortion access.

A federal judge ruled that the U.S. Food and Drug Administration’s 2023 restrictions on mifepristone, a drug used to terminate early pregnancies, are unlawful and require review. The restrictions, challenged by abortion providers in Kansas, Montana, and Virginia, include mandatory certification for pharmacies and clinicians and risk acknowledgment forms, which plaintiffs argue are excessive and medically unnecessary.